Market Research Industry Reports

Sumitomo Dainippon Pharma Co Ltd (4506) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd (4506) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 6
List of Figures 7
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19
Venture Financing 21
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22
Matrizyme Pharma Raises USD9 Million in Financing 23
Tolero Pharma Raises US$3.33 Million In Venture Financing 24
Elevation Pharma Secures US$30 Million In Series B Financing 25
Private Equity 27
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27
Partnerships 28
Tolero Pharma Enters into Research Agreement with AbbVie 28
Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30
Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32
Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34
FunPep Enters into Research Agreement with Sumitomo Dainippon 35
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37
Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38
ex scientia Enters into Research Agreement with Sunovion Pharma 39
Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40
Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43
Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45
Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48
Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50
Licensing Agreements 51
Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53
Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55
Sunovion Pharma Enters into Licensing Agreement with Novartis 56
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59
SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62
Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65
Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69
Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72
MannKind Enters Into Licensing Agreement With Tolero Pharma For Brutons Tyrosine Kinase Inhibitors 73
Equity Offering 74
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 78
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 79
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 81
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 82
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 83
Debt Offering 84
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 84
Asset Transactions 86
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87
Acquisition 88
Sumitomo Dainippon Pharma Acquires Tolero Pharma 88
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90
Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For US$16 Million 92
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 93
Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95
Sumitomo Dainippon Pharma Co Ltd - Key Competitors 97
Sumitomo Dainippon Pharma Co Ltd - Key Employees 98
Sumitomo Dainippon Pharma Co Ltd - Locations And Subsidiaries 100
Head Office 100
Other Locations & Subsidiaries 100
Recent Developments 103
Strategy And Business Planning 103
Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 103
Financial Announcements 104
Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019 104
May 11, 2018: Sumitomo Dainippon Pharma: Summary of Consolidated Financial Results for the Year Ended March 31, 2018 107
Corporate Communications 112
Sep 03, 2018: Sumitomo Dainippon Pharma announces personnel changes 112
Jun 28, 2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan 113
Jun 15, 2018: Sumitomo Dainippon Pharma Announces Management Changes 114
May 11, 2018: Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions 115
Feb 23, 2018: Sumitomo Dainippon Pharma Names Hiroshi Nomura As President And CEO 116
Mar 29, 2017: Sumitomo Dainippon Pharma announces Changes in Executive Officers 117
Mar 22, 2017: Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical and Establishment of Global Head of Oncology 118
Legal and Regulatory 120
Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinsons disease 120
Government and Public Interest 121
Jun 01, 2017: Sumitomo Dainippon Pharma Contributes funding to the Global Health Innovative Technology Fund (GHIT Fund) for the Second Period 121
Product Approvals 122
Jul 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome 122
Feb 28, 2017: Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a SAKIGAKE Product by Japans Ministry of Health, Labour and Welfare 123
Clinical Trials 124
Jul 31, 2018: Kyoto University to begin trials of iPS cells to treat Parkinsons 124
Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 125
May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017 126
Other Significant Developments 127
May 31, 2018: Sumitomo Dainippon Pharma Joins IFPMA as New Member[TOPC : Pharma - Sumitomo Dainippon Pharma Co Ltd] 127
Jul 04, 2017: Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S. 128
Apr 10, 2017: Hitachi is selected by Sumitomo Dainippon Pharma for Automated Cell Mass Culture Equipment for Regenerative Medicine using Human iPS Cells 129
Appendix 130
Methodology 130
About GlobalData 130
Contact Us 130
Disclaimer 130

List Of Tables


Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22
Matrizyme Pharma Raises USD9 Million in Financing 23
Tolero Pharma Raises US$3.33 Million In Venture Financing 24
Elevation Pharma Secures US$30 Million In Series B Financing 25
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27
Tolero Pharma Enters into Research Agreement with AbbVie 28
Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30
Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32
Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34
FunPep Enters into Research Agreement with Sumitomo Dainippon 35
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37
Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38
ex scientia Enters into Research Agreement with Sunovion Pharma 39
Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40
Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43
Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45
Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48
Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50
Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53
Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55
Sunovion Pharma Enters into Licensing Agreement with Novartis 56
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59
SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62
Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65
Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69
Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72
MannKind Enters Into Licensing Agreement With Tolero Pharma For Brutons Tyrosine Kinase Inhibitors 73
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 78
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 79
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 81
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 82
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 83
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 84
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87
Sumitomo Dainippon Pharma Acquires Tolero Pharma 88
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90
Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For US$16 Million 92
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 93
Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95
Sumitomo Dainippon Pharma Co Ltd, Key Competitors 97
Sumitomo Dainippon Pharma Co Ltd, Key Employees 98
Sumitomo Dainippon Pharma Co Ltd, Other Locations 100
Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 101

List Of Figures


Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Sumitomo Dainippon Pharma Co Ltd (4506) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas

USD 250View Report

Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review

Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been

USD 125View Report

Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review

Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been

USD 125View Report

Sumitomo Dainippon Pharma Co., Ltd. - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Sumitomo Dainippon Pharma Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Sumitomo Dainippon Pharma Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

USD 350View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Sep 2018
No. of Pages :130
Country :Japan
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube